Moneycontrol PRO
HomeNewsBusinessAlembic Pharma gets USFDA nod for antihypertensive tablets

Alembic Pharma gets USFDA nod for antihypertensive tablets

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Olmesartan Medoxomil and Amlodipine tablets, Alembic Pharmaceuticals said in a BSE filing.

July 18, 2017 / 15:59 IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Alembic Pharmaceuticals today said it has received approval from the US health regulator for generic Olmesartan Medoxomil and Amlodipine tablets used for the treatment of hypertension.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Olmesartan Medoxomil and Amlodipine tablets, Alembic Pharmaceuticals said in a BSE filing.

The approval is for the tablets in the strengths of 20mg/5mg, 40 mg/5 mg, 20 mg/10 mg and 40 mg/10 mg, it added.

The product is generic version of Daiichi Sankyo Inc's Azor tablets in the same strengths, Alembic Pharma said.

The tablets are indicated for the treatment of hypertension, alone or with antihypertensive agents to lower blood pressure, it added.

According to IMS the Olmesartan Medoxomil and Amlodipine tablets had an estimated market size of USD 312 million for twelve months ending December 2016.

The company has a total of 61 ANDA approvals from the USFDA.

Shares of Alembic Pharmaceuticals today closed 1.75 per cent up at Rs 554.95 per scrip on BSE.

first published: Jul 18, 2017 03:49 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347